Clinical & experimental findings

Human randomized studyAbstract inspected

In a multicentre, randomized, double-blind crossover trial of 20 patients aged 17 to 43 with Unverricht-Lundborg disease (progressive myoclonus epilepsy), piracetam 24 g/day produced a statistically significant improvement in the primary myoclonus rating scale (p=0.005) and in motor-impairment, functional-disability and investigator/patient global-assessment subscores, with a significant linear dose-response relationship across 9.6, 16.8 and 24 g/day doses; adverse effects were described as few, mild and transient. This condition-specific result at very high research doses does not establish memory enhancement in healthy adults.^[1]

Small short crossover study without washout between phases; not a healthy-person cognition trial.
Full text could not be obtained despite multiple lawful attempts (PMC Open Access mirror, Europe PMC full-text XML, and the PMC website itself, which returned an automated-browser challenge); inspection remains abstract-only, corroborated by two independently retrieved, word-for-word concordant abstract records (PubMed and Europe PMC).
Abstract-checked; no qualified clinical review.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-08 · Prior batch record retained as unverified historical input pending fresh review.

2026-09-09 · nootropic batch: reopened source(s) via NCBI E-utilities / PMC Open Access; verified and refined with precise numbers/limitations from the source.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo.
Koskiniemi M, Van Vleymen B, Hakamies L, Lamusuo S, Taalas J. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):344-8. DOI: 10.1136/jnnp.64.3.344. PMCID: PMC2169975. 1998-03. PMID:9527146 · PMCID:PMC2169975 · DOI:10.1136/jnnp.64.3.344 Abstract only.
Inspected location: PubMed/MEDLINE abstract and Europe PMC abstractText (concordant, independently retrieved) via NCBI E-utilities and Europe PMC REST
Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts

Fresh PubMed EUtils retrieval for inherited lead PMID 9527146; identity, abstract and linked corrections checked where an abstract existed.
https://pubmed.ncbi.nlm.nih.gov/9527146/ — abstract; PubMed abstract: Methods: Unverricht-Lundborg disease crossover without washout; Results: myoclonus scores

View this compound in the research library →

Related records in this class

Grouped under Other compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.